SCHEMBL17347738

SCHEMBL17347738

CCCCCCn1c(=O)[nH]c2ccc(NC(C)=O)cc2c1=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ERCC1 P07992 2/20 0.61
▸ FEN1 P39748 2/20 0.61
▸ ERCC4 Q92889 2/20 0.61
▸ DNASE1 P24855 1/20 0.61
▸ MAPT P10636 6/20 0.57
▸ POLB P06746 1/20 0.57
▸ NPC1 O15118 1/20 0.56
▸ KDM4E B2RXH2 6/20 0.56
▸ MEN1 O00255 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ RGS12 O14924 1/20 0.56
▸ ALDH1A1 P00352 4/20 0.56
▸ HPGD P15428 4/20 0.56
▸ HSD17B10 Q99714 4/20 0.56
▸ GAA P10253 2/20 0.56
▸ TP53 P04637 2/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ GLA P06280 1/20 0.48
▸ ESR1 P03372 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17335952 0.83 ERCC1 (0.62) ERCC1FEN1ERCC4DNASE1POLB
SCHEMBL17335955 0.83 ERCC1 (0.62) ERCC1FEN1ERCC4DNASE1NPC1
SCHEMBL17347885 0.82 ERCC1 (0.56) ERCC1FEN1ERCC4DNASE1MAPT
SCHEMBL17335966 0.81 ERCC1 (0.55) ERCC1FEN1ERCC4DNASE1KDM4E
SCHEMBL17335954 0.81 ERCC1 (0.55) ERCC1FEN1ERCC4DNASE1MAPT
SCHEMBL17347739 0.80 ERCC1 (0.59) ERCC1FEN1ERCC4DNASE1POLB
SCHEMBL17335950 0.79 ERCC1 (0.58) ERCC1FEN1ERCC4DNASE1POLB
SCHEMBL9401066 0.79 DRD2 (0.56) ERCC1FEN1ERCC4DNASE1MAPT
SCHEMBL9400900 0.77 DRD2 (0.56) ERCC1FEN1ERCC4DNASE1MAPT
SCHEMBL18763315 0.76 ALDH1A1 (0.54) ERCC1FEN1ERCC4DNASE1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170114029-A1 TREATMENT OF CHAGAS DISEASE SYNGENE INTERNATIONAL LIMITED (IN) 2017-04-27 — — US disclosed
US-20170114029-A1 TREATMENT OF CHAGAS DISEASE SYNGENE INTERNATIONAL LIMITED (IN) 2017-04-27 — — US disclosed
WO-2015189595-A1 TREATMENT OF CHAGAS DISEASE UNIVERSITY OF DUNDEE (GB) 2015-12-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170114029-A1 TREATMENT OF CHAGAS DISEASE CXCR4, CBR1, CHRM1 ERCC1 2255/4885FEN1 4772/4885ERCC4 2078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback